Assessment of the antihypercholesterolemic drug, Probucol, in benign prostatic hyperplasia.
Seventy patients were administered either Probucol, an anti-cholesterol agent or a placebo in a double blind manner for a period of 1 year in an effort to assess the effectiveness of this agent in treating benign prostatic hyperplasia. Sensation of incomplete voiding and peak and mean voiding flow rates showed a trend which indicated a therapeutic effect, however, this effect was comparable for both placebo and the drug group. This is interpreted as indicating the effectiveness of standard urologic therapy, and double blind trials are therefore needed in assessing different agents for the medical management of benign prostatic hyperplasia.
D002784:Cholesterol / Q000097:blood; D004311:Double-Blind Method; D004341:Drug Evaluation; D006801:Humans; D008297:Male; D010636:Phenols / Q000627:therapeutic use*; D011341:Probucol / Q000627:therapeutic use*; D011470:Prostatic Hyperplasia / Q000150:complications / Q000188:drug therapy*; D011897:Random Allocation; D014555:Urination Disorders / Q000188:drug therapy / Q000209:etiology; D014563:Urodynamics / Q000187:drug effects
D010636:Phenols; D002784:Cholesterol; D011341:Probucol